NCT06508229View on ClinicalTrials.gov

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2028

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Adebrelimab

adebrelimab, IV

DRUG

albumin paclitaxel

albumin paclitaxel, iv

DRUG

Nedaplatin

Nedaplatin，IV

All Listed Sponsors

lead

Harbin Medical University

OTHER